Abstract
2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have